Ferrari: Lecture XV Flashcards

Genome Editing: BTHAL and Sickle Cell Disease

1
Q

What causes sickle cell disease (anemia)?

A

single point mutation of the β-globin gene

*β-thalassemia is a mutation of the β-globin gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What does the point mutation in sickle cell disease do?

A

substitues glutamic acid with a valine in position 6, which gives rise to a mutant globin chain called HbS (S stands for sickle)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the pahthophyiology of HbS

A

during deoxygenation, HbS forms fibers in a process called polymerization

the fibers are toxic and lead to the erythrocytes becoming dehydrated and assume an elongated sickle shape

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the clinical symptoms of sickle cell disease?

A

haemolytic anemia (not severe)

vaso-occlusion (very painful, patients go to the ER and treated with opiods)

disease is associated with morbidity and mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List the pathway of sickle cell disease:

A

HbS is polymerized

RBC are sickled

vaso-occlusion

haemolysis is possible, which leads to heme group being released → induces endothelial dysfunction → cytokines are released → inflamed microenvironment → sterile inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the epidemiology of sickle cell disease?

A

most common genetic disorder (almost 300,000 newborns are born with this condition)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is a highly debated hypothesis of sickle cell disease’s correlation with malaria?

A

the mutation protects from malaria infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the life expectancy of people with anemia?

A

less than 30 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does hemolytic anemia do? and leads to?

A

blocks small blood vessels leads to vaso-occlusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is acute stress syndrome?

A

symptom of anemia which requires immediate hospitalization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are chronic complication associated with sickle cell disease?

A

general vasculopathy and progressive ischemic organ damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the treatments available for sickle cell disease?

A

blood transfusions during vaso-occlusive crisis to dilate HbS with new blood and bone marrow transplantations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why is it hard to find donors for sickle cell disease?

A

Majority of patients are not Caucasian so there is different major histocompatibility complexes (MHC) so it is more dificult to find suitable donors

also ethical/religious reasons can prevent bone marrow donation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Is there a cure for sickle cell disease?

A

no, there is not a pharmacological or definitive cure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the HPFH condition?

A

hereditary persistence of fetal haemoglobin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why is it important to understand hereditary persistence of fetal hemoglobin?

A

it is important to understand gene editing for sickle cell disease or β-thalassemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is HPFH condition associated with?

A

high level of fetal hemoglobin in adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the molecular cause of the reactivation of HbF?

A

point mutations in the HGB gene or locus (promoter of 𝜸 globin) → non-deletional HPFH: disruption of repressor binding site

deletions in the HBG gene or locus downstream the 𝜸 globin gene → deletion of HPFH: deletion of repressor binding sites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How do we correct defective β-globin gene cells?

A

homology direct repair (HDR), which only has 20%-40% efficiency if I am very good

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How were the repressors of the 𝜸-globin gene identified?

A

using GWAS (genome-wide association studies) by which the correlation of SNPs (single-nucleotide polymorphisms) has been highlighted

21
Q

What are the 3 regions that were identified as associated with high levels of HbF?

A

intergenic region between HBS1L and MYB on chr 6

β-locus: reactivates 𝜸-globin

erythroid enhancer on the promoter of BCL11A gene on chr 2:erythroid form of BCL11A is a silencer for the 𝜸-genes

22
Q

What can silence 𝜸-genes?

A

BCL11A

LFR

23
Q

How does BCL11A silence 𝜸-genes?

A

forms a complex with GATA1 (activator), FOG1 (activator), and NuRD complex 9repressor complex) to bind to DNA and have a negative effect on 𝜸-gene promoters → repression

24
Q

Can 𝜸-gene reactivation be induced?

A

yes by silencing the 𝜸-gene repressors (BCL11A or LRF)

25
Q

List the 4 techniques that can be used to induce HPFH (treat β-hemoglobinopathies):

A

targeting the BCL11A erythroid enhancer

introducing non-deletional HPFH

introducing deletional HPFH

gene repair

26
Q

Describe targeting the BCL11A erythroid enhancer:

A

done with zinc finger, Cas9…

enhancer is deleted to obtain less BCL11A expression → 𝜸-gene expression is reactivated

27
Q

Describe introduction of non-deletional HPFH:

A

mutations are created on binding sites of the promoters of 𝜸-genes so the repressors do not bind

28
Q

Describe the introduction of deletional HPFH:

A

zinc fingers, Cas9, NHEJ delete repressor binding sites, resulting in big deletions

29
Q

Describe gene repair:

A

NHEJ is used (high efficiency) to introduce the repair of the mutated gene through HDR

*limitation is DR occurs at a low frequency

30
Q

Why can HbF be therapeutic?

A

it has anti-sickling properties, and it increases the total levels of hemoglobin in β-thalassemia patients (not SCD)

31
Q

HbF impedes the ____ of HbS → ____

A

polymerization

anti-sickling molecule

32
Q

Describe the therapeutic approach for β-thalassemia:

!!

A

presence of HbF is induced → no polymerization → sickling of cells is prevented → HbS is diluted → formation of polymers is less → cells have both HbS and HbS → HbF repels HbS naturally

33
Q

What was an advantage with the experiment using CRISPR/Cas9 β-globin gene targeting in HPSC?

A

it had the 1st use of ribonuclear particle (Rnp) was used, which allowed for a higher efficiency in indels (of cutting) → higher eficiency in tageting

34
Q

BCL11A is an ____

A

enhancer disruptor

35
Q

What is important when using zinc fingers?

A

detection of off-target sites because the system is very specific and does not cut undesired regions

36
Q

BCL11A is an ____ ____ enhancer.

A

erythroid specific

37
Q

If the ___ ___ is eliminated, there will not be expression of BCL11A in ALL the cells.

A

coding sequence

38
Q

If we target the specific erythroid enhancer sequence, ___ is deleted only from erythroid cells.

A

BCL11A

39
Q

What does a mutation on the 𝜸 promoter create?

A

e-box motif which composes a consensus sequence for an activator, TAL1 erythroid specific activator

40
Q

Where is the TAL1 erythroid specific activator created?

A

antisense strand of the 𝜸-globin promoter

41
Q

Why are we creating a site for an activator?

A

it is something that occurs naturally in patients with HPFH mutation

42
Q

What 2 methods can be used to create a site for an activator?

A

mutation on the -175 nt in the promoter of the 𝜸-gene

through genome editing

43
Q

How can we generate a deletional HPFH mutation? What cell line was used for this technique?

A

using 2 guides that simultaneously target the sequence and then have Cas9 cut and create small deletions

HUDEP cell line

44
Q

What has shown the most efficient approach in the clinical phase?

A

elimination of the erythroid specific BCL11A expression

45
Q

What was the aim of the 2 trials related to BTHAL and SCD?

A

elevate HbF levels to achieve a therapeutic effect

46
Q

What did the trial conducted using ex-vivo technique with CRISPR-Cas9 demonstrate?

A

disrupting the GATA1 binding site in BCL11A promoter only in the erythroid lineage causes the % of HbF to increase by 30% with respect to the control…this provided proof of concept of reactivation of HbF in vitro

47
Q

Why can we perform lentiviral vector gene addition to correct mice, but not perform the preclinical correction on β-thalassemia murine model or SCD murine model?

A

the mouse switch from HbF to HbA happens before birth

genome editing works well in humans, but not in mice (usually the opposite)

48
Q

What was incredible after 20 weeks in the β-thalassemia patient?

A

no more transfusions were needed after 20 weeks